chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19
Symptoms: Nasal congestion, SARS-CoV-2 test
Clinical narrative: tested positive for Covid/Oropharyngeal Pain/Pyrexia/Cough; tested positive for Covid/Oropharyngeal Pain/Pyrexia/Cough; mental fogginess; stuffy nose; tiredness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FEELING ABNORMAL (non-serious) with onset 24Aug2022, outcome "unknown", described as "mental fogginess"; NASAL CONGESTION (non-serious) with onset 24Aug2022, outcome "unknown", described as "stuffy nose"; FATIGUE (non-serious) with onset 24Aug2022, outcome "unknown", described as "tiredness"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 27Aug2022, outcome "unknown" and all described as "tested positive for Covid/Oropharyngeal Pain/Pyrexia/Cough". The patient underwent the following laboratory tests and procedures: Body temperature: (24Aug2022) 101 Fahrenheit, notes: fever of 101F; SARS-CoV-2 test: (27Aug2022) Positive, notes: My sister tested positive for Covid on 27Aug2022.  Clinical course: The reporter's sister tested positive for Covid on 27Aug2022. Her symptoms started Wednesday night (24Aug2022) as a sore throat and progressed to a fever of 101F, stuffy nose, coughing, tiredness and mental fogginess. She received two Pfizer Covid-19 vaccines and booster. She declined consent to contact but agreed to provide lot numbers at a later date.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Breakthrough case of COVID/ Symptoms were mild moderate headache, mild cough, nasal congestion/runny nose; Breakthrough case of COVID/ Symptoms were mild moderate headache, mild cough, nasal congestion/runny nose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), on 25Mar2021 as dose 2, single (Batch/Lot number: unknown) and on 05Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Breakthrough case of COVID/ Symptoms were mild moderate headache, mild cough, nasal congestion/runny nose". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Breakthrough case of COVID. Clinical course: Breakthrough case of COVID after receiving the primary series of the vaccine and a booster dose. Booster dose was administered on 05Nov2021, and primary series completed on 25Mar2021. Symptoms were mild moderate headache, mild cough, nasal congestion/runny nose.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19, COVID19, COVID19
Symptoms: Drug ineffective, Suspected COVID-19
Clinical narrative: Covid; Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 66-year-old patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Aug2022, outcome "unknown" and all described as "Covid". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cough, Headache, Pain, Pneumonia, Pulmonary congestion
Clinical narrative: Covid; Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 66-year-old patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Aug2022, outcome "unknown" and all described as "Covid". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia, Sinusitis
Clinical narrative: Covid; Covid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 66-year-old patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Aug2022, outcome "unknown" and all described as "Covid". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: had covid in Feb; had covid in Feb; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) and as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Feb2022, outcome "unknown" and all described as "had covid in Feb". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Feb2022) Positive, notes: Also had Covid in Feb.  Clinical course: Patient had Covid in Feb and would never get another shot on tell anyone else to get it. Patient gave up a lot and almost my life getting your shot.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: Allergy to vaccine
Clinical narrative: This is a spontaneous report received from contactable reporter(s) (Other HCP). Other Case identifier(s): 2022NVX-000002979 (RA). A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALLERGY TO VACCINE (non-serious), outcome "unknown", described as "allergic reaction". Additional information: It was reported the patient had an allergic reaction following the first dose of the Pfizer vaccine. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19, UNK
Symptoms: Drug ineffective, SARS-CoV-2 test, Suspected COVID-19
Clinical narrative: COVID-19; COVID-19; MARKETING PROGRAM NAME NOT AVALIBLE  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4515639-00 (AbbVie).  A 58-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown), all intramuscular for covid-19 immunisation; upadacitinib (RINVOQ), (ongoing) (Batch/Lot number: unknown), oral for rheumatoid arthritis. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Jul2022, outcome "recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jul2022) Unknown Results. The action taken for upadacitinib was dosage not changed.  The reporter considered "covid-19" related to BNT162b2. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided and known drug safety profile, the causality between the suspect drug BNT162B2 in the occurrence of the event   Drug ineffective , Suspected COVID-19 cannot be excluded.
Sex: U
Vaccine: COVID19
Symptoms: Deafness unilateral
Clinical narrative: loss total hearing in right ear; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (005570). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2 , single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEAFNESS UNILATERAL (medically significant), outcome "unknown", described as "loss total hearing in right ear".  Clinical course: Just loss total hearing in right ear. Read where Pfizer vaccine might cause this. I had all Pfizer Covid vaccinations and boosters. What do you know about this possibility?  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Culture, Cytomegalovirus test, Investigation, Polymerase chain reaction, Vaccination site pain
Clinical narrative: vulvar pain and the presence of ulcers on the labia minora; arm pain at the site of injection; This is a literature report.  A 17-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "post-menarchal female" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, single), for COVID-19 Immunisation. The following information was reported: VULVAL ULCERATION (medically significant), outcome "recovered", described as "vulvar pain and the presence of ulcers on the labia minora"; VACCINATION SITE PAIN (non-serious), outcome "recovered", described as "arm pain at the site of injection". The patient underwent the following laboratory tests and procedures: Culture: Negative; Positive, notes: for Staphylococcus aureus; Cytomegalovirus test: unknown result, notes: were ordered but not obtained by the patient; Epstein bar virus: unknown result, notes: were ordered but not obtained by the patient; Polymerase chain reaction: Negative. Therapeutic measures were taken as a result of vulval ulceration, vaccination site pain. She was started on methylprednisolone for seven days and ibuprofen and later with amoxicillin.  Clinical course: The patient developed fevers and arm pain at the site of injection one day after receiving the second dose of the Pfizer-BioNTech COVID-19 Vaccine, followed by vulvar pain and the presence of ulcers on the labia minora. A genital culture was positive for Staphylococcus aureus and she subsequently started amoxicillin. A herpes simplex virus (HSV) polymerase chain reaction (PCR) test and fungal culture were negative. Cytomegalovirus (CMV) and epstein bar virus (EBV) titers were ordered but not obtained by the patient. Full resolution of the ulcers and symptoms were noted at follow-up on day 20.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the event VULVAL ULCERATION and BNT162B2.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201104494 Same Article/Drug/event and different patient;US-PFIZER INC-202201104493 Same Article/Drug/event and different patient;
Sex: F
Vaccine: COVID19
Symptoms: Vulval ulceration
Clinical narrative: vulvar pain and the presence of ulcers on the labia minora; arm pain at the site of injection; This is a literature report.  A 17-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "post-menarchal female" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, single), for COVID-19 Immunisation. The following information was reported: VULVAL ULCERATION (medically significant), outcome "recovered", described as "vulvar pain and the presence of ulcers on the labia minora"; VACCINATION SITE PAIN (non-serious), outcome "recovered", described as "arm pain at the site of injection". The patient underwent the following laboratory tests and procedures: Culture: Negative; Positive, notes: for Staphylococcus aureus; Cytomegalovirus test: unknown result, notes: were ordered but not obtained by the patient; Epstein bar virus: unknown result, notes: were ordered but not obtained by the patient; Polymerase chain reaction: Negative. Therapeutic measures were taken as a result of vulval ulceration, vaccination site pain. She was started on methylprednisolone for seven days and ibuprofen and later with amoxicillin.  Clinical course: The patient developed fevers and arm pain at the site of injection one day after receiving the second dose of the Pfizer-BioNTech COVID-19 Vaccine, followed by vulvar pain and the presence of ulcers on the labia minora. A genital culture was positive for Staphylococcus aureus and she subsequently started amoxicillin. A herpes simplex virus (HSV) polymerase chain reaction (PCR) test and fungal culture were negative. Cytomegalovirus (CMV) and epstein bar virus (EBV) titers were ordered but not obtained by the patient. Full resolution of the ulcers and symptoms were noted at follow-up on day 20.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the event VULVAL ULCERATION and BNT162B2.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201104494 Same Article/Drug/event and different patient;US-PFIZER INC-202201104493 Same Article/Drug/event and different patient;
Sex: U
Vaccine: COVID19
Symptoms: Disease recurrence, Drug ineffective, Suspected COVID-19
Clinical narrative: had Covid twice; had Covid twice; had Covid twice; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 65-year-old patient received BNT162b2 (BNT162B2), on 18Oct2021 as dose 1, single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset 20Dec2021, outcome "unknown" and all described as "had Covid twice"; DISEASE RECURRENCE (medically significant) with onset 22Jan2022, outcome "unknown", described as "had Covid twice". Clinical course: The patient stated, "I had my first Pfizer COVID vaccine 18Oct2021. Can the new B variant vaccine be my second dose? I'm 65 and have had COVID twice (20Dec& 22Jan)."  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Peripheral coldness
Clinical narrative: the patient's hands got even colder than after she use Suprep. Her hands were freezing; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 2022BTE00712.  A 68-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PERIPHERAL COLDNESS (non-serious), outcome "unknown", described as "the patient's hands got even colder than after she use Suprep. Her hands were freezing". Therapeutic measures were taken as a result of peripheral coldness.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Disease recurrence, Drug ineffective, SARS-CoV-2 test
Clinical narrative: tested positive; tested positive; symtoms returned and we tested Pos; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "tested positive"; DISEASE RECURRENCE (medically significant), outcome "unknown", described as "symtoms returned and we tested Pos". The event "tested positive" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive; Negative; Positive. Therapeutic measures were taken as a result of drug ineffective, COVID-19. Clinical course: The reporter's husband (patient) received the BNT162B2 COVID-19 vaccines, and tested positive again for COVID despite receiving the BNT162B2 vaccines. The patient woke up with scratchy throats, had fever and headaches during the night. Took the test and was pos, called his Dr. Took the Paxlovid for 5 days, tested Neg. Then 3 and 4 days later symtoms returned and he tested.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201022236 Same reporter/vaccine/event, different patient;US-PFIZER INC-202201105638 Same reporter/vaccine/event, different patient;
Age: 49.0
Sex: M
Vaccine: MNQ
Symptoms: Diplopia, Multiple sclerosis, Photophobia
Clinical narrative: has been diagnosed with MS; developed photophobia, the light sensitivity turned to double vision; light sensitivity turned to double visiondeveloped photophobia, the light sensitivity turned to double vision; Initial information received on 24-Aug-2022 regarding an unsolicited valid serious case from a patient sister.  This case involves a 49-year-old male patient who experienced has been diagnosed with multiple sclerosis (MS), developed photophobia, the light sensitivity turned to double vision while receiving vaccine Meningococcal A-C-Y-W135 (D CONJ) Vaccine [Menactra].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date in Jun or Jul of this year 2022, the patient was doubted to received suspect Menactra vaccine at (unknown: formulation, strength, dose, lot number, route in unknown administration site) for immunization. Information regarding batch number requested.  On unknown date in 2022 within 24 to 48 hours of receiving the vaccine, patient developed photophobia and the light sensitivity turned to double vision (diplopia). Patient had developed other significant symptoms and after lots of testing.  On unknown date in 2022, the patient developed a serious has been diagnosed with MS (multiple sclerosis) at unknown latency. This event was assessed as medically significant.  Action taken: Not applicable.  Corrective treatment: not reported.  At time of reporting, the outcome was Unknown for  the events.; Sender's Comments: Sanofi company comment 29-Aug-2022: This case involves a 49-year-old male patient who experienced has been diagnosed with multiple sclerosis (MS), developed photophobia, the light sensitivity turned to double vision after receiving Menactra vaccine. Further information regarding concurrent condition during vaccination, previous vaccination, concomitant medication and tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed for complete assessment of the case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, COVID-19, Catheterisation cardiac abnormal, Computerised tomogram thorax normal, Coronary artery stenosis
Clinical narrative: Age: 79 y.o. Admit Date: 7/17/2022  7:54 PM Discharge Date: 7/19/2022  Unit: 3A131/3A131A   Discharge Diagnosis: Principal Problem:   COVID-19 Active Problems:   CAD (coronary artery disease)   CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min   NSTEMI (non-ST elevated myocardial infarction)       HPI AND HOSPITAL COURSE   History of Present Illness:  As per admission H&P, "Patient is a 79 y.o. male with a history of ASHD. Short of breath a week brought on by COVID infection. Has been on paxlovid and not better. Worse with exertion. To ED with shortness of breath and "hurts all over". Fever still and coughing. Some nausea and diarrhea. "       Hospital Course: Patient, is a 79 y.o. male who presented with SOA.   He was managed for the following:   * COVID-19 COVID-19 infection - Found to be covid positive.  He was treated with remdesivir.  He was stable  on room air, no indication for steroids.  he felt improved, discharge home in stable condition.    Elevated d-dimer - BLE US negative for DVT.  CT PE study negative for PE.    Elevated troponin - to 0.14. Type 2 MI Cardiology was consulted.  LHC showed patent stents, small OM branch with 70% stenosis.  No new stents placed.  Imdur was added per cardiology.  F/u outpatient.                Physical Exam on the Date of Discharge: Blood pressure 137/58, pulse 84, temperature 98 °F (36.7 °C), temperature source Oral, resp. rate 18, height 5' 5" (165.1 cm), weight 85.5 kg (188 lb 6.4 oz), SpO2 98 %. General - NAD, appears stated age  HEENT - EOMI, PER, MMM, oropharynx clear Chest - lungs clear bilaterally, no w/r/r, normal effort Heart - RRR, NS1S2, no m/r/g Abdomen - Soft, non-tender, non-distended, +BS,  Extremities - warm, no edema Psych - AAOx3, affect appropriate Skin - no rash, dry   Discharge Condition: improved   Disposition: home
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Diarrhoea, Dry skin, Dyspnoea, Dyspnoea exertional
Clinical narrative: Age: 79 y.o. Admit Date: 7/17/2022  7:54 PM Discharge Date: 7/19/2022  Unit: 3A131/3A131A   Discharge Diagnosis: Principal Problem:   COVID-19 Active Problems:   CAD (coronary artery disease)   CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min   NSTEMI (non-ST elevated myocardial infarction)       HPI AND HOSPITAL COURSE   History of Present Illness:  As per admission H&P, "Patient is a 79 y.o. male with a history of ASHD. Short of breath a week brought on by COVID infection. Has been on paxlovid and not better. Worse with exertion. To ED with shortness of breath and "hurts all over". Fever still and coughing. Some nausea and diarrhea. "       Hospital Course: Patient, is a 79 y.o. male who presented with SOA.   He was managed for the following:   * COVID-19 COVID-19 infection - Found to be covid positive.  He was treated with remdesivir.  He was stable  on room air, no indication for steroids.  he felt improved, discharge home in stable condition.    Elevated d-dimer - BLE US negative for DVT.  CT PE study negative for PE.    Elevated troponin - to 0.14. Type 2 MI Cardiology was consulted.  LHC showed patent stents, small OM branch with 70% stenosis.  No new stents placed.  Imdur was added per cardiology.  F/u outpatient.                Physical Exam on the Date of Discharge: Blood pressure 137/58, pulse 84, temperature 98 °F (36.7 °C), temperature source Oral, resp. rate 18, height 5' 5" (165.1 cm), weight 85.5 kg (188 lb 6.4 oz), SpO2 98 %. General - NAD, appears stated age  HEENT - EOMI, PER, MMM, oropharynx clear Chest - lungs clear bilaterally, no w/r/r, normal effort Heart - RRR, NS1S2, no m/r/g Abdomen - Soft, non-tender, non-distended, +BS,  Extremities - warm, no edema Psych - AAOx3, affect appropriate Skin - no rash, dry   Discharge Condition: improved   Disposition: home
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Fibrin D dimer increased, Nausea, Pain, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Age: 79 y.o. Admit Date: 7/17/2022  7:54 PM Discharge Date: 7/19/2022  Unit: 3A131/3A131A   Discharge Diagnosis: Principal Problem:   COVID-19 Active Problems:   CAD (coronary artery disease)   CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min   NSTEMI (non-ST elevated myocardial infarction)       HPI AND HOSPITAL COURSE   History of Present Illness:  As per admission H&P, "Patient is a 79 y.o. male with a history of ASHD. Short of breath a week brought on by COVID infection. Has been on paxlovid and not better. Worse with exertion. To ED with shortness of breath and "hurts all over". Fever still and coughing. Some nausea and diarrhea. "       Hospital Course: Patient, is a 79 y.o. male who presented with SOA.   He was managed for the following:   * COVID-19 COVID-19 infection - Found to be covid positive.  He was treated with remdesivir.  He was stable  on room air, no indication for steroids.  he felt improved, discharge home in stable condition.    Elevated d-dimer - BLE US negative for DVT.  CT PE study negative for PE.    Elevated troponin - to 0.14. Type 2 MI Cardiology was consulted.  LHC showed patent stents, small OM branch with 70% stenosis.  No new stents placed.  Imdur was added per cardiology.  F/u outpatient.                Physical Exam on the Date of Discharge: Blood pressure 137/58, pulse 84, temperature 98 °F (36.7 °C), temperature source Oral, resp. rate 18, height 5' 5" (165.1 cm), weight 85.5 kg (188 lb 6.4 oz), SpO2 98 %. General - NAD, appears stated age  HEENT - EOMI, PER, MMM, oropharynx clear Chest - lungs clear bilaterally, no w/r/r, normal effort Heart - RRR, NS1S2, no m/r/g Abdomen - Soft, non-tender, non-distended, +BS,  Extremities - warm, no edema Psych - AAOx3, affect appropriate Skin - no rash, dry   Discharge Condition: improved   Disposition: home
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Troponin increased, Ultrasound Doppler normal
Clinical narrative: Age: 79 y.o. Admit Date: 7/17/2022  7:54 PM Discharge Date: 7/19/2022  Unit: 3A131/3A131A   Discharge Diagnosis: Principal Problem:   COVID-19 Active Problems:   CAD (coronary artery disease)   CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min   NSTEMI (non-ST elevated myocardial infarction)       HPI AND HOSPITAL COURSE   History of Present Illness:  As per admission H&P, "Patient is a 79 y.o. male with a history of ASHD. Short of breath a week brought on by COVID infection. Has been on paxlovid and not better. Worse with exertion. To ED with shortness of breath and "hurts all over". Fever still and coughing. Some nausea and diarrhea. "       Hospital Course: Patient, is a 79 y.o. male who presented with SOA.   He was managed for the following:   * COVID-19 COVID-19 infection - Found to be covid positive.  He was treated with remdesivir.  He was stable  on room air, no indication for steroids.  he felt improved, discharge home in stable condition.    Elevated d-dimer - BLE US negative for DVT.  CT PE study negative for PE.    Elevated troponin - to 0.14. Type 2 MI Cardiology was consulted.  LHC showed patent stents, small OM branch with 70% stenosis.  No new stents placed.  Imdur was added per cardiology.  F/u outpatient.                Physical Exam on the Date of Discharge: Blood pressure 137/58, pulse 84, temperature 98 °F (36.7 °C), temperature source Oral, resp. rate 18, height 5' 5" (165.1 cm), weight 85.5 kg (188 lb 6.4 oz), SpO2 98 %. General - NAD, appears stated age  HEENT - EOMI, PER, MMM, oropharynx clear Chest - lungs clear bilaterally, no w/r/r, normal effort Heart - RRR, NS1S2, no m/r/g Abdomen - Soft, non-tender, non-distended, +BS,  Extremities - warm, no edema Psych - AAOx3, affect appropriate Skin - no rash, dry   Discharge Condition: improved   Disposition: home
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Oedema peripheral, Pain, Pyrexia, Rash
Clinical narrative: Systemic: Allergic: Rash (specify: facial area, extremeties)-Severe, Systemic: Body Aches Generalized-Severe, Systemic: Chills-Severe, Systemic: Fever-Severe, Additional Details: patient states she has hives only on the left side of her body and swelling on the left side of her body. She stated that she had previously gotten vaccinated and had swelling on her armpit area and controlled it with ice pack, second vaccine much more swelling
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling, Urticaria
Clinical narrative: Systemic: Allergic: Rash (specify: facial area, extremeties)-Severe, Systemic: Body Aches Generalized-Severe, Systemic: Chills-Severe, Systemic: Fever-Severe, Additional Details: patient states she has hives only on the left side of her body and swelling on the left side of her body. She stated that she had previously gotten vaccinated and had swelling on her armpit area and controlled it with ice pack, second vaccine much more swelling
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Injection site warmth
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: tender and warm to touch at injections site
Age: 63.0
Sex: F
Vaccine: PNC20
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Nausea
Clinical narrative: Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Allergic: Itch Generalized-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Body Aches Generalized-Mild, Systemic: Fever-Mild, Systemic: Nausea-Mild, Additional Details: pt came to the pharmacy and complaint about the high fever for past 3 days 99F and above. the size of rash in the left arm was about the palm of the hand. looked red and tender, hot to touch. pt was very itchy at the site. suggested to take benadryl
Age: 63.0
Sex: F
Vaccine: PNC20
Symptoms: Pain, Pruritus, Pyrexia, Rash, Rash erythematous
Clinical narrative: Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Allergic: Itch Generalized-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Body Aches Generalized-Mild, Systemic: Fever-Mild, Systemic: Nausea-Mild, Additional Details: pt came to the pharmacy and complaint about the high fever for past 3 days 99F and above. the size of rash in the left arm was about the palm of the hand. looked red and tender, hot to touch. pt was very itchy at the site. suggested to take benadryl
Age: 63.0
Sex: F
Vaccine: PNC20
Symptoms: Skin warm, Tenderness
Clinical narrative: Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Allergic: Itch Generalized-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Body Aches Generalized-Mild, Systemic: Fever-Mild, Systemic: Nausea-Mild, Additional Details: pt came to the pharmacy and complaint about the high fever for past 3 days 99F and above. the size of rash in the left arm was about the palm of the hand. looked red and tender, hot to touch. pt was very itchy at the site. suggested to take benadryl
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Basal ganglia infarction, Blister, Blood glucose increased, COVID-19
Clinical narrative: Physician Discharge Summary   Patient ID: MRN:  Name: private Age: 67 y.o. Birthday:   Admit Date: 7/18/2022 10:56 AM Discharge Date:  7/21/2022 Unit: 5J505/5J505A Admitting Physician:  Discharge Physician:  MD   Discharge Diagnosis: Principal Problem:   Slurred speech Active Problems:   Type 2 diabetes mellitus with stage 4 chronic kidney disease, without long-term current use of insulin   Chronic renal disease, stage IV   COVID-19 virus infection   Vomiting   Cellulitis of fourth toe   CKD (chronic kidney disease) stage 5, GFR less than 15 ml/min   Generalized weakness       HPI:    Patient is a 67 y.o. female with ckd stage 4, DM, cva. Patient reported that for the past 4 days, she noted erythema and swelling over the right 4th toe associated with blister forming on right arm that became erythematous. For the past 2 days, she had episodes of vomiting, worsening weakness and fever. She denies shortenss of breath nor cough. She was seen at UC and was given antibiotics. She went to bed last night doing well but shen she work up at 9:30 AM, daughter reported her speech was slurred. She denies hemiparesis, no headache. She was seen in ER and stroke alert sounded. CT head is unremarkable. Not candidate for TPA as it is unclear as to LKN. She was admitted. Speech improved when I saw her. she was continued on asa , statin.    She has covid 19. There was an occasion her O2 sat dropped to less than 94%. She was offered remdesivir but she refused. She agreed on iv decadron.    She has wound on the right arm and 4th toe. She was given iv unasyn and doxy. She was seen by wound care. This is currently improved.    She has CKD stage 5. She was seen by nephrology. I held amaryl as she has ckd that increases risk for hypoglycemia. Blood sugar slightly elevated due to steroid use   She is doing better. Will discharge. Advised to quarantine for several more days.      Hospital Course: No notes on file   She was admitted to medical floor in airborne isolation because of covid 19 + test. She was seen by neurology. MRI of the head showed:  No definitive acute infarct.  2. Chronic lacunar infarcts are visualized within the bilateral basal ganglia,  right thalamus, cerebellum, and cerebral white matter.  3. Mild additional white matter disease, likely representing chronic small  vessel ischemic disease.  4. Foci of T1 hypointensity are identified within the corpus callosum.  Demyelination is within the differential.  5. Mild atrophy.  6. Bilateral proptosis.  7. Paranasal sinus disease.  8. Additional findings described above.        Physical Exam on the Date of Discharge: Physical exam:  General Appearance: alert, NAD  Neck: no JVD, no LN enlargement  Lungs: clear, no wheezing   Heart: RRR, S1 S2 heard  Abdomen / GI: soft, non-tender, no ascites  Extremities / musculoskeletal:  edema, no synovitis   Skin: no rash, dry skin  Neuro: follows commands, moves extremities
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Cerebral atrophy, Cerebral small vessel ischaemic disease, Computerised tomogram head normal, Dysarthria, Erythema
Clinical narrative: Physician Discharge Summary   Patient ID: MRN:  Name: private Age: 67 y.o. Birthday:   Admit Date: 7/18/2022 10:56 AM Discharge Date:  7/21/2022 Unit: 5J505/5J505A Admitting Physician:  Discharge Physician:  MD   Discharge Diagnosis: Principal Problem:   Slurred speech Active Problems:   Type 2 diabetes mellitus with stage 4 chronic kidney disease, without long-term current use of insulin   Chronic renal disease, stage IV   COVID-19 virus infection   Vomiting   Cellulitis of fourth toe   CKD (chronic kidney disease) stage 5, GFR less than 15 ml/min   Generalized weakness       HPI:    Patient is a 67 y.o. female with ckd stage 4, DM, cva. Patient reported that for the past 4 days, she noted erythema and swelling over the right 4th toe associated with blister forming on right arm that became erythematous. For the past 2 days, she had episodes of vomiting, worsening weakness and fever. She denies shortenss of breath nor cough. She was seen at UC and was given antibiotics. She went to bed last night doing well but shen she work up at 9:30 AM, daughter reported her speech was slurred. She denies hemiparesis, no headache. She was seen in ER and stroke alert sounded. CT head is unremarkable. Not candidate for TPA as it is unclear as to LKN. She was admitted. Speech improved when I saw her. she was continued on asa , statin.    She has covid 19. There was an occasion her O2 sat dropped to less than 94%. She was offered remdesivir but she refused. She agreed on iv decadron.    She has wound on the right arm and 4th toe. She was given iv unasyn and doxy. She was seen by wound care. This is currently improved.    She has CKD stage 5. She was seen by nephrology. I held amaryl as she has ckd that increases risk for hypoglycemia. Blood sugar slightly elevated due to steroid use   She is doing better. Will discharge. Advised to quarantine for several more days.      Hospital Course: No notes on file   She was admitted to medical floor in airborne isolation because of covid 19 + test. She was seen by neurology. MRI of the head showed:  No definitive acute infarct.  2. Chronic lacunar infarcts are visualized within the bilateral basal ganglia,  right thalamus, cerebellum, and cerebral white matter.  3. Mild additional white matter disease, likely representing chronic small  vessel ischemic disease.  4. Foci of T1 hypointensity are identified within the corpus callosum.  Demyelination is within the differential.  5. Mild atrophy.  6. Bilateral proptosis.  7. Paranasal sinus disease.  8. Additional findings described above.        Physical Exam on the Date of Discharge: Physical exam:  General Appearance: alert, NAD  Neck: no JVD, no LN enlargement  Lungs: clear, no wheezing   Heart: RRR, S1 S2 heard  Abdomen / GI: soft, non-tender, no ascites  Extremities / musculoskeletal:  edema, no synovitis   Skin: no rash, dry skin  Neuro: follows commands, moves extremities
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Exophthalmos, Lacunar infarction, Limb injury, Magnetic resonance imaging head abnormal, Oxygen saturation decreased
Clinical narrative: Physician Discharge Summary   Patient ID: MRN:  Name: private Age: 67 y.o. Birthday:   Admit Date: 7/18/2022 10:56 AM Discharge Date:  7/21/2022 Unit: 5J505/5J505A Admitting Physician:  Discharge Physician:  MD   Discharge Diagnosis: Principal Problem:   Slurred speech Active Problems:   Type 2 diabetes mellitus with stage 4 chronic kidney disease, without long-term current use of insulin   Chronic renal disease, stage IV   COVID-19 virus infection   Vomiting   Cellulitis of fourth toe   CKD (chronic kidney disease) stage 5, GFR less than 15 ml/min   Generalized weakness       HPI:    Patient is a 67 y.o. female with ckd stage 4, DM, cva. Patient reported that for the past 4 days, she noted erythema and swelling over the right 4th toe associated with blister forming on right arm that became erythematous. For the past 2 days, she had episodes of vomiting, worsening weakness and fever. She denies shortenss of breath nor cough. She was seen at UC and was given antibiotics. She went to bed last night doing well but shen she work up at 9:30 AM, daughter reported her speech was slurred. She denies hemiparesis, no headache. She was seen in ER and stroke alert sounded. CT head is unremarkable. Not candidate for TPA as it is unclear as to LKN. She was admitted. Speech improved when I saw her. she was continued on asa , statin.    She has covid 19. There was an occasion her O2 sat dropped to less than 94%. She was offered remdesivir but she refused. She agreed on iv decadron.    She has wound on the right arm and 4th toe. She was given iv unasyn and doxy. She was seen by wound care. This is currently improved.    She has CKD stage 5. She was seen by nephrology. I held amaryl as she has ckd that increases risk for hypoglycemia. Blood sugar slightly elevated due to steroid use   She is doing better. Will discharge. Advised to quarantine for several more days.      Hospital Course: No notes on file   She was admitted to medical floor in airborne isolation because of covid 19 + test. She was seen by neurology. MRI of the head showed:  No definitive acute infarct.  2. Chronic lacunar infarcts are visualized within the bilateral basal ganglia,  right thalamus, cerebellum, and cerebral white matter.  3. Mild additional white matter disease, likely representing chronic small  vessel ischemic disease.  4. Foci of T1 hypointensity are identified within the corpus callosum.  Demyelination is within the differential.  5. Mild atrophy.  6. Bilateral proptosis.  7. Paranasal sinus disease.  8. Additional findings described above.        Physical Exam on the Date of Discharge: Physical exam:  General Appearance: alert, NAD  Neck: no JVD, no LN enlargement  Lungs: clear, no wheezing   Heart: RRR, S1 S2 heard  Abdomen / GI: soft, non-tender, no ascites  Extremities / musculoskeletal:  edema, no synovitis   Skin: no rash, dry skin  Neuro: follows commands, moves extremities
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Pyrexia, SARS-CoV-2 test positive, Vomiting
Clinical narrative: Physician Discharge Summary   Patient ID: MRN:  Name: private Age: 67 y.o. Birthday:   Admit Date: 7/18/2022 10:56 AM Discharge Date:  7/21/2022 Unit: 5J505/5J505A Admitting Physician:  Discharge Physician:  MD   Discharge Diagnosis: Principal Problem:   Slurred speech Active Problems:   Type 2 diabetes mellitus with stage 4 chronic kidney disease, without long-term current use of insulin   Chronic renal disease, stage IV   COVID-19 virus infection   Vomiting   Cellulitis of fourth toe   CKD (chronic kidney disease) stage 5, GFR less than 15 ml/min   Generalized weakness       HPI:    Patient is a 67 y.o. female with ckd stage 4, DM, cva. Patient reported that for the past 4 days, she noted erythema and swelling over the right 4th toe associated with blister forming on right arm that became erythematous. For the past 2 days, she had episodes of vomiting, worsening weakness and fever. She denies shortenss of breath nor cough. She was seen at UC and was given antibiotics. She went to bed last night doing well but shen she work up at 9:30 AM, daughter reported her speech was slurred. She denies hemiparesis, no headache. She was seen in ER and stroke alert sounded. CT head is unremarkable. Not candidate for TPA as it is unclear as to LKN. She was admitted. Speech improved when I saw her. she was continued on asa , statin.    She has covid 19. There was an occasion her O2 sat dropped to less than 94%. She was offered remdesivir but she refused. She agreed on iv decadron.    She has wound on the right arm and 4th toe. She was given iv unasyn and doxy. She was seen by wound care. This is currently improved.    She has CKD stage 5. She was seen by nephrology. I held amaryl as she has ckd that increases risk for hypoglycemia. Blood sugar slightly elevated due to steroid use   She is doing better. Will discharge. Advised to quarantine for several more days.      Hospital Course: No notes on file   She was admitted to medical floor in airborne isolation because of covid 19 + test. She was seen by neurology. MRI of the head showed:  No definitive acute infarct.  2. Chronic lacunar infarcts are visualized within the bilateral basal ganglia,  right thalamus, cerebellum, and cerebral white matter.  3. Mild additional white matter disease, likely representing chronic small  vessel ischemic disease.  4. Foci of T1 hypointensity are identified within the corpus callosum.  Demyelination is within the differential.  5. Mild atrophy.  6. Bilateral proptosis.  7. Paranasal sinus disease.  8. Additional findings described above.        Physical Exam on the Date of Discharge: Physical exam:  General Appearance: alert, NAD  Neck: no JVD, no LN enlargement  Lungs: clear, no wheezing   Heart: RRR, S1 S2 heard  Abdomen / GI: soft, non-tender, no ascites  Extremities / musculoskeletal:  edema, no synovitis   Skin: no rash, dry skin  Neuro: follows commands, moves extremities
Age: 57.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Mass, Ultrasound scan abnormal
Clinical narrative: 5 X 5 cm mass lower R deltoid muscle pt stated occurred after 1st dose.
Age: 16.0
Sex: F
Vaccine: MENB, MNQ
Symptoms: Injection site erythema, Injection site nodule, Injection site swelling, Injection site warmth, Pain
Clinical narrative: Small knot with redness at injection sire, arm swollen down to elbow, warm to touch. Patient complains of pain to touch or movement. Given cold compress instructions along with benadryl. Prescribed prednisone 50mg.
Age: 16.0
Sex: F
Vaccine: MENB, MNQ
Symptoms: Tenderness
Clinical narrative: Small knot with redness at injection sire, arm swollen down to elbow, warm to touch. Patient complains of pain to touch or movement. Given cold compress instructions along with benadryl. Prescribed prednisone 50mg.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID vaccine breakthrough case
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Appetite disorder, Dyskinesia, Weight abnormal
Clinical narrative: COVID vaccine breakthrough case
Age: 92.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Pfizer 1/28/21  EL9265 dose 2 Pfizer 2/25/21  EN6202
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: C-reactive protein increased
Clinical narrative: Elevated cardiac CRP.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Bronchitis, Influenza virus test negative, SARS-CoV-2 test negative
Clinical narrative: Bronchitis.